Holen Sie sich die Stockscreener-App
4.84
5.22%
0.24
Schlusskurs vom Vortag:
$4.60
Offen:
$4.61
24-Stunden-Volumen:
692.39K
Relative Volume:
0.79
Marktkapitalisierung:
$468.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-238.77M
KGV:
-0.1805
EPS:
-26.808
Netto-Cashflow:
$-216.62M
1W Leistung:
+1.89%
1M Leistung:
+46.22%
6M Leistung:
-6.38%
1J Leistung:
-62.45%
1-Tages-Spanne:
$4.61
$4.8683
1-Wochen-Bereich:
$4.33
$5.131
52-Wochen-Spanne:
$2.7601
$13.11
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.84 | 500.47M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Candlestick Signal Suggests Reversal in Alumis Inc.2025 Retail Activity & Entry Point Strategy Guides - beatles.ru
Analyzing Alumis Inc. with multi timeframe chartsDollar Strength & Entry and Exit Point Strategies - Newser
Alumis Inc. stock daily chart insightsJuly 2025 Decliners & Target Return Focused Picks - Newser
What high frequency data says about Alumis Inc.July 2025 Closing Moves & High Yield Stock Recommendations - Newser
Is Alumis Inc. meeting your algorithmic filter criteriaTrade Entry Report & AI Enhanced Market Trend Forecasts - Newser
Is Alumis Inc. stock a good hedge against inflation2025 Year in Review & Growth Oriented Trade Recommendations - Newser
Predicting Alumis Inc. trend using moving averagesCPI Data & Free Daily Entry Point Trade Alerts - Newser
How high can Alumis Inc. stock goEarnings Recap Report & Daily Profit Focused Screening - Newser
Real time social sentiment graph for Alumis Inc.2025 Fundamental Recap & Technical Buy Zone Confirmation - Newser
Will Alumis Inc. price bounce be sustainableRecession Risk & Verified Entry Point Detection - Newser
Smart tools for monitoring Alumis Inc.’s price actionJuly 2025 Selloffs & Risk Managed Investment Signals - Newser
Reversal indicators forming on Alumis Inc. stock2025 Biggest Moves & Safe Swing Trade Setups - Newser
Alumis Inc. Reports Q2 2025 Earnings and Strategic Advances - TipRanks
Why Alumis Inc. stock attracts strong analyst attention2025 Volume Leaders & Real-Time Stock Entry Alerts - Newser
Equities Analysts Set Expectations for Alumis Q3 Earnings - Defense World
Will breakout in Alumis Inc. lead to full recovery2025 Macro Impact & Low Risk Entry Point Tips - Newser
What makes Alumis Inc. stock price move sharplyQuarterly Portfolio Review & Advanced Swing Trade Entry Plans - Newser
Can momentum traders help lift Alumis Inc.Market Movement Recap & Stepwise Trade Signal Implementation - Newser
Is Alumis Inc. a stock for growth or value investorsJuly 2025 Momentum & Detailed Earnings Play Strategies - classian.co.kr
Morgan Stanley Lowers Alumis (NASDAQ:ALMS) Price Target to $22.00 - Defense World
Can machine learning forecast Alumis Inc. recoveryWeekly Investment Recap & Stock Timing and Entry Methods - Newser
Alumis Inc. Builds Base for Possible ReboundWeekly Risk Summary & Consistent Profit Trading Strategies - metal.it
Alumis Inc. Stock Support and Resistance Levels You Should KnowWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
Alumis Inc.: A Biopharma Bargain Amid Clinical Catalysts and Analyst Optimism - AInvest
Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - simplywall.st
Alumis Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - 富途牛牛
How Alumis Inc. stock performs during market volatilityPortfolio Value Report & Daily Stock Trend Reports - thegnnews.com
Relative strength of Alumis Inc. in sector analysisJuly 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Alumis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Alumis Inc. shares fall 1.36% intraday after reporting Q2 2025 financial results and merger with Acelyrin. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Alumis stock amid post-merger decline - Investing.com
Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic Positioning - TipRanks
Alumis Misses Q2 Revenue as Costs Jump - AOL.com
Alumis Q2 Revenue Down 5% YoY, Cash to Fund Ops into 2027 - AInvest
Alumis reports Q2 revenue $2.67M, consensus $2.43M - TipRanks
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Alumis Hits Major Milestone in Psoriasis Drug Development, Strengthens Pipeline with $486M War Chest - Stock Titan
Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of “Buy” by Brokerages - Defense World
What momentum shifts mean for Alumis Inc.Free Entry Plan for Oversold Reversal Stocks - Newser
Is Alumis Inc. reversing from oversold territoryPredictive Short-Term Market Reversal Alerts - Newser
While institutions invested in Alumis Inc. (NASDAQ:ALMS) benefited from last week's 4.1% gain, individual investors stood to gain the most - uk.finance.yahoo.com
Alumis Inc.'s (NASDAQ:ALMS) market cap touched US$444m last week, benefiting both retail investors who own 38% as well as institutions - simplywall.st
Alumis Inc. (NASDAQ:ALMS) Stock Position Boosted by Bank of New York Mellon Corp - Defense World
Alumis Inc. Concludes 2025 Annual Stockholders Meeting - The Globe and Mail
How strong is Alumis Inc. company’s balance sheetMassive stock growth - Jammu Links News
What is the dividend policy of Alumis Inc. stockGet alerts on high-potential stock breakouts - Jammu Links News
Should I hold or sell Alumis Inc. stock in 2025Build a portfolio that outperforms consistently - Jammu Links News
When is Alumis Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
What drives Alumis Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
How volatile is Alumis Inc. stock compared to the marketInvest in stocks with strong fundamentals - Jammu Links News
What are analysts’ price targets for Alumis Inc. in the next 12 monthsCapitalize on trading strategies that deliver - Jammu Links News
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):